Article Information
History
- August 25, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Juan Kou1,
- Yingying Zhang1,
- Feng Zhou1,
- Cornelia Sindermann2,
- Christian Montag2,
- Benjamin Becker1 and
- Keith M Kendrick1,*
- 1The Clinical Hospital of Chengdu Brain Science Institute, MOE Key Laboratory for Neuroinformation, University of Electronic Science and Technology of China, Chengdu 611731, China
- 2Department of Molecular Psychology, Institute of Psychology and Education, Ulm University, Ulm, Germany
- ↵* Corresponding author: Keith M. Kendrick, Institute: The Clinical Hospital of Chengdu Brain Science, MOE Key Laboratory for NeuroInformation, University: University of Electronic Science and Technology of China, Street Name & Number: No. 2006, Xiyuan Ave, West Hi-tech Zone, Chengdu, 611731, China. Tel: 86-28-83201358. Fax: 86-28-83201358. E-mail: kkendrick{at}uestc.edu.cn
Posted August 25, 2020.
A randomized trial shows dose-frequency and genotype may determine the therapeutic efficacy of intranasal oxytocin
